Here's why the shares of biotech Impedimed Limited are soaring today

Medical device maker Impedimed Limited (ASX:IPD) has seen its share price soar after launching its first health and wellness product. Is it a buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The shares of medical device maker Impedimed Limited (ASX: IPD) are flying higher today after it announced that its first product for the health and wellness market was available for global pre-order.

In lunchtime trading, shares were up more than 6% at $1.635.

SOZO is the first product on its new population health platform allowing consumers to track everything from their body composition, fluid status, and hydration levels through a variety of settings.

According to the release SOZO is an intuitive digital health device and wellness platform which combines bioimpedance spectroscopy technology with artificial intelligence, creating a rapid, non-invasive scan of a person's body providing a precise and repeatable snapshot.

Furthermore, predictive analytics in SOZO can access cloud-based historical health data to create a customised plan for the user's personal health and wellness goals, which it believes will help individuals better manage their health conditions and track their wellness goals.

Managing director and CEO Richard Carreon had this to say on the launch:

"We are fulfilling our vision of population health in the ecosystem of health and wellness. The SOZO platform and our growing pipeline of new and innovative products will position us at the forefront of the digital health revolution. Innovation is at our core and will become the life blood of the organisation. The future is now."

I like the look of the product and believe that it will be appealing to gyms, personal trainers, athletes, and fitness enthusiasts like myself. There is undoubtedly a growing market for health tracking and as such, I expect the product could do very well.

But I wouldn't personally recommend making an investment purely on this announcement. Impedimed certainly has a lot going for it at the moment and could well have an exciting future. But until I see pre-order sales figures for SOZO and strong sales growth in its L-Dex lymphoedema detection product, I think I will be sitting this one out.

Until then I would suggest investors take a look at already profitable companies in the healthcare space such as CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH).

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »